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1. Introduction  
Brain natriuretic peptide (BNP) is a hormone that is secreted by the heart, especially from 
the ventricle (Sudoh et al., 1988; Yasue et al., 1994). The plasma BNP concentrations (BNP 
levels) are correlated positively with the left ventricular end-diastolic pressure and 
negatively with the left ventricular ejection fraction (Yoshimura et al., 1993; Maeda et al., 
1998), so BNP levels should be measured to evaluate left ventricular function. BNP levels 
have proved to be good markers of congestive heart failure. In addition, BNP levels are 
useful in screening test for left ventricular dysfunction and also heart disease.  
Some studies have shown that BNP levels have a prognostic value of mortality and 
morbidity in patients with chronic heart failure (Maeda et al., 2000; Anand et al., 2003), in 
general populations (Wang et al., 2004) and in clinical practice (Tsuchida & Tanabe, 2008). 
However, the prognostic value of BNP levels in patients with atrial fibrillation (AF) is not 
well known. This study investigated the relations of BNP levels to cardiovascular events 
and death in patients with AF. 
Hohnloser et al. suggested that warfarin therapy was needed in patients with paroxysmal 
AF similarly as in those with sustained AF (Hohnloser et al., 2007). Another report showed 
that, if sinus rhythm was maintained with antiarrhythmic therapy, the prognosis of the 
patients with paroxsmal AF for ischemic stroke was better than those with permanent AF 
(Komatsu et al., 2004). We examined the necessity of warfarin therapy in patients with 
paroxysmal AF as in those with chronic AF.  
Furthermore, CHADS2 score is known to be very useful to decide the indication of warfarin 
therapy in patients with AF (Gage et al., 2001). The patients with CHADS2 score of 2 or more 
are recommended to take warfarin therapy, those with CHADS2 score of 1 to take Warfarin 
or antiplatelet drugs, and those with CHADS2 score of 0 need not any take warfarin. We 
investigated the usefulness of BNP as an aid in CHADS2 score to decide the indication of 
warfarin therapy in patients with CHADS2 score of 0 or 1.  
2. Subjects and methods 
2.1 Subjects 
This study included 371 consecutive outpatients with AF in the Tsuchida Clinic of Internal 
Medicine and Cardiology (23-93 years with an average age of 69.5±10.8 years; 205 men and 
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166 women; 231 paroxysmal AF and 140 chronic AF), whose BNP levels were measured to 
evaluate left ventricular function from 1999 to 2002. The patients were treated according to 
the relevant guidelines and followed up until 31 December 2006. The mean follow-up period 
was 5.4years (max: 7.5 years). Diagnosis was based on history, physical examination, 
laboratory findings, chest X-rays, electrocardiograms and echocardiograms. Paroxysmal AF 
was defined as AF that terminated spontaneously within 7 days after onset. Chronic AF was 
defined clinically when defibrillation of paroxysmal AF was unsuccessful (permanent AF) 
or AF was continuously observed for more than 6 months (persistent AF).  
2.2 Methods 
BNP levels were measured by the immunoradiometric assay method using a Shionoria BNP 
assay kit (Shionogi, Osaka, Japan) for the one-point blood sample taken in a sitting position. 
Some studies of patients with heart failure (Latini et al., 2004; Tsutamoto et al., 1997) showed 
that BNP levels of more than about 100 pg/ml were significantly related to mortality and 
morbidity, so the patients were stratified into two groups based on cut-off levels of BNP 
(<100 pg/ml and ≧100 pg/ml). 
The primary endpoint was a composite of cardiovascular events (hospitalization and death). 
Components of the endpoints included the following: heart failure, coronary heart disease 
events (acute myocardial infarction, unstable angina), stroke (ischemic, hemorrhagic), 
arrhythmia, dissecting aneurysm, peripheral arterial disease, infective endocarditis, acute 
myocarditis, renal infarction, pulmonary infarction, embolism of the superior mesenteric 
artery, and sudden cardiac death. The first of these events was noted as the primary event. 
Any component of a composite primary endpoint, for which a patient could be counted 
once in each category, was treated as a second endpoint. Death from any cause was also 
designated a secondary endpoint. Furthermore, patients with paroxysmal AF were observed 
for the development of chronic AF. The study protocol was approved by the Ethics 
Committee of Tsuchida Clinic of Internal Medicine and Cardiology. 
2.3 Statistical analysis 
Values are shown as mean±standard deviation (SD). Time-to-event curves for the endpoints 
were estimated by the Kaplan-Meier method for the entire follow-up period. The log-rank 
test was used to examine the association of BNP levels. Hazard ratio (HR) and 95% 
confidence interval (CI) were calculated and adjusted for age, sex, the presence or absence of 
hypertension, diabetes mellitus, and hyperlipidemia with the Cox’s proportional hazards 
model. All analyses were performed with the use of StatView (version 5.0). Significance 
levels were p < 0.05 in these analyses. 
3. Results 
3.1 Patient characteristics 
Clinical characteristics are summarized in Table 1. This study included 371 patients: 
valvular disease was found in 57 (15%); congestive heart failure (CHF) in 58 (16%); coronary 
artery disease (CAD) in 47 (13%), old myocardial infarction (OMI) in 16 (4%), angina 
pectoris (ANG) in 31 (8%); prior stroke in 35 (9%); hypertrophic cardiomyopathy (HCM) in 
19 (5%); dilated cardiomyopathy (DCM) in 10 (3%); prior pacemaker operation in 12 (3%); 
hypertension in 228 (62%); diabetes mellitus in 63 (17%); dyslipidemia in 104 (28%); 
including some patients with more than one disease. In comparing chronic AF with 
paroxysmal AF, there were more valvular disease, CHF, and prior stroke in patients with 
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 All PAF CAF
p Value 
(n=371) (n=231) (n=140) 
Age (years) 69.5±10.8 68.4±10.9 71.3±10.2 0.0119 
Male gender 205 (55%) 121 (52%) 84 (60%) 0.1534 
BNP (pg/ml) 96 57 160 <0.0001 
Cardiovascular disease  
  Valvular disease 57 (15%) 22 (10%) 35 (25%) <0.0001 
  CHF 58 (16%) 12 (5%) 46 (33%) <0.0001 
  CAD 47 (13%) 16 (7%) 13 (9%) 0.1925 
     OMI 16 (4%) 11 (5%) 5 (4%) 0.5855 
     ANG 31 (8%) 5 (3%) 8 (6%) 0.1531 
  Prior stroke 35 (9%) 15 (7%) 20 (14%) 0.0127 
  HCM 19 (5%) 10 (4%) 9 (6%) 0.3752 
  DCM 10 (3%) 2 (1%) 8 (6%) 0.0127 
  Prior pacemaker operation 12 (3%) 4 (2%) 8 (6%) 0.0356 
  Hypertension 228 (62%) 147 (64%) 81 (58%) 0.2688 
  Diabetes mellitus 63 (17%) 33 (14%) 30 (21%) 0.0760 
  Dyslipidemia 104 (28%) 70 (30%) 34 (24%) 0.2121 
CHADS2 score 1.43 1.23 1.76 <0.0001 
                  0 82 (22%) 60 (26%) 22 (16%)  
                  1 138 (37%) 95 (41%) 43 (31%)  
                  2 86 (23%) 46 (20%) 40 (29%)  
                  3 38 (10%) 21 (9%) 17 (12%)  
                  4-6 27 (7%) 9 (4%) 18 (13%)  
Medication  
  Warfarin 90 (24%) 38 (17%) 52 (37%) <0.0001 
  Antiplatelet drugs 177 (48%) 99 (43%) 78 (56%) 0.0162 
  Beta-blocker 24 (7%) 20 (9%) 4 (3%) 0.0277 
  ACEI/ARB 55 (15%) 40 (17%) 15 (11%) 0.1033 
  Ca blocker 196 (53%) 128 (55%) 68 (49%) 0.2018 
  Digitalis 270 (73%) 173 (75%) 97 (69%) 0.2408 
  Antiarrhythmic drugs 77 (21%) 65 (28%) 12 (9%) <0.0001 
  Thiazide 72 (19%) 25 (11%) 47 (34%) <0.0001 
  Antialdosterone agents 60 (16%) 20 (9%) 40 (29%) <0.0001 
  Nitrates 27 (7%) 17 (7%) 10 (7%) 0.9382 
  Statins 95 (26%) 60 (26%) 35 (25%) 0.8355 
＊PAF: paroxymal atrial fibrillation, CAF: chronic atrial fibrillation 
＊ACE: angiotension converting enzyme inhibitor, ARB: angiotensin receptor blocker 
Table 1. Characteristics of the Study Population   
chronic AF than in those with paroxysmal AF. And BNP levels in patients with chronic AF 
(160 pg/ml) were about 3 folds compared to with paroxysmal AF (57 pg/ml, during sinus 
rhythm).  
Patients with chronic AF had a mean CHADS2 score of 1.76 compared with 1.23 in those 
with paroxysmal AF (p<0.0001). The reason for the higher mean CHADS2 score in patients 
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with chronic AF was probably because of older age, the presence of more structural heart 
disease (valvular disease, DCM, prior pacemaker operation and CHF) and prior stroke. 
The prior use of warfarin, wntiplatelet drugs, beta-blocker, thiazide and antialdosterone 
drugs was significantly higher in chronic AF. And the prior use of antiarrhythmic drugs was 
significantly higher in paroxysmal AF. 
3.2 Kaplan-Meier curves for the endpoints and Incidence of death or cardiovascular 
events 
Patients were stratified into two groups based on cut-off level of BNP (100 pg/ml), and a 
cumulative cardiovascular event-free curve was constructed according to Kaplan-Meier 
analysis. Cumulative cardiovascular event-free rate, as evaluated by Kaplan-Meier analysis, 
was significantly lower with a BNP level≥100 pg/ml (p<0.0001) (Figure 1). Similarly, in 
secondary analyses (cardiovascular mortality, all-cause mortality, heart failure, ischemic 
stroke, development of paroxysmal AF into chronic AF), cumulative survival rate (event-
free rate) was significantly lower with a BNP level≥100 pg/ml (Figure 2, Figure 3, Figure4, 
Figure 5, Figure 6). But only with regard to coronary heart disease events, the cumulative 
event-free rate was not significantly associated with the BNP level. 
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Fig. 1. Kaplan-Meier Curve for Cardiovascular Events 
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Fig. 3. Kaplan-Meier Curve for All-Cause Mortality 
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Fig. 4. Kaplan-Meier Curve for Heart Failure 
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Fig. 6. Kaplan-Meier Curve for Development of Paroxysmal AF into Chronic AF 
 
 Number of events 
HR (95%CI) p Value BNP≧100 BNP<100 
(n=112) (n=259) 
Primary endpoint     
Cardiovascular events 58 (52%) 38 (15%) 3.9 (2.6-6.0) <0.0001 
Secondary endpoints     
Cadiovascular mortality 35 (31%) 11 ( 4%) 5.2 (2.6-10.5) <0.0001 
All-cause mortality 47 (42%) 33 (13%) 2.3 (1.4-3.7) 0.0005 
Heart failure 30 (27%) 8 ( 3%) 11.0 (4.9-24.5) <0.0001 
Coronary h.d. events 2 ( 2%) 4 ( 2%) 0.9 (0.1-5.3) 0.8840 
Ischemic stroke 19 (17%) 18 ( 7%) 2.1 (1.1-4.1) 0.0296 
Development of PAF into CAF 
    (PAF, n=231) 
10/31 
(32%) 
29/200 
(15%) 
2.8 (1.3-6.1) 0.0098 
 
Table 2. Incidence of Cardiovascular Events in Patients with AF 
During a mean follow-up of 5.4 years, the number of cardiovascular events was 96/371 
(26%): heart failure 38, coronary heart disease events 6 (acute myocardial infarction 6), 
stroke 38 (ischemic 37, hemorhagic 1), arrhythmia 7 (sick sinus syndrome 4, 
atrioventricular block 1, ventricular tachycardia 1), embolism of superior mesenteric 
artery 1, renal infarction 1, others 5. The number of deaths from cardiovascular disease 
was 46/371 (12%): heart failure 17, coronary heart disease events 2 (acute myocardial 
infarction 2), stroke 17 (ischemic 16, hemorhagic 1), arrythmia 2 (ventricular fibrillation 2), 
embolism of superior mesenteric artery 2, dissecting aneurysm 1, others 5. The number of 
deaths from all causes was 80/371 (22%): cardiovascular disease 46 (as was stated above), 
malignant tumor 20 (lung 4, stomach 3, colon 5, pancreas 3, esophagus 2, others 3), 
pneumonia and chronic obstructive pulmonary disease 3, renal failure 2, liver cirrhosis 2, 
others 7.  
A BNP level≥100 pg/ml was associated with a HR (95% CI) of 3.94 (2.57-6.04) for 
cardiovascular events compared with a BNP<100 pg/ml (p<0.0001), 5.18 (2.55-10.52) for 
Log-rank, p=0.0098 
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cardiovascular mortality (p<0.0001), 2.32 (1.44-3.72) for all-cause mortality (p=0.0005), 11.01 
(4.94-24.54) for heart failure (p<0.0001), 2.11 (1.08-4.14) for ischemic stroke (p=0.0247) , 2.80 
(1.28-6.10) for development of paroxysmal AF into chronic AF (p=0.0098); however, it was 
0.87 (0.14-5.34) for coronary heart disease events (p=0.8840). In addition, paroxysmal AF 
developed into chronic AF in 39 of 231 patients (16.9%, 3.1% of patients per year). 
3.3 Incidence of stroke in patients with paroxysmal AF and chronic AF 
Furthermore, the incidence of ischemic stroke was significantly with BNP≥100 pg/ml than 
with BNP<100 pg/ml (HR: 5.31, 95%CI: 1.49-18.89, p=0.0812) by univariate analysis (Figure 
8), whereas in patients with chronic AF, it was not significantly associated with the BNP 
levels (HR: 1.02, 95% CI: 0.48-2.18, p=0.3623) (Figure 9). 
 
 
No. at Risk 
Paroxysmal AF            231    212    202   188     171   153    133 
Chronic AF                  140    118    109    100       91    78      69 
Fig. 7. Kaplan-Meier Curve for Ischemic Stroke in Patients with paroxysmal AF and chronic 
AF 
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No. at Risk 
BNP<100 pg/ml       59       51      49      46       43     34        32 
BNP≧100 pg/ml      81      67      60      54       48      43       37 
Fig. 9. Kaplan-Meier Curve for Ischemic Stroke in Patients with Chronic AF 
3.4 CHADS2 Score and Incidence of Ischemic stroke 
Based on Kaplan-Meier analysis of five groups stratified by CHADS2 score (0, 1, 2, 3, 4-6) in 
Figure 10, it was found that as CHADS2 score was higher, the cumulative event-free rate for 
ischemic stroke decreased significantly (p<0.0001). As detailed in Table 3, there was the 
number of prior use of warfarin and the incidence of ischemic stroke, stratified by CHADS2 
score.  
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Fig. 10. Kaplan-Meier Curve for Ischemic Stroke, Stratified by CHADS2 Score 
Log-rank, p=0.3623 
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CHADS2  
score 
No. of patients 
(n=371) 
Prior use of warfarin
(n=90) 
No. of stroke 
(n=37) 
0 82 16 (20%) 3 ( 4%) 
1 138 25 (18%) 9 ( 7%) 
2 86 25 (29%) 13 (15%) 
3 38 10 (26%) 6 (16%) 
4-6 27 14 (52%) 6 (22%) 
Table 3.  Incidence of Stroke and Prior Use of Warfarin, Stratified by CHADS2 Score 
In patients with CHADS2 score of 0 or 1, a BNP level≧100 pg/ml was associated with a HR 
(95% CI) of 3.84 (1.18-12.47) for ischemic stroke compared with a BNP < 100 pg/ml 
(p=0.0254) (Figure 11).  
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No. at Risk 
BNP<100 pg/ml      178    160    154    147     136    123     113 
BNP≧100 pg/ml      42      36      35      27       25      23       20 
Fig. 11. Kaplan-Meier Curve for Ischemic Stroke in Patients with CHADS2 Score of 0 or 1 
4. Discussion 
4.1 BNP and the risk of cardiovascular events and death in patients with AF 
BNP is a hormone that is secreted by the heart, especially from the ventricle (Sudoh et al., 
1988; Yasue et al., 1994), and BNP levels are useful in diagnosis and screening for left 
ventricular dysfunction and heart failure. Furthermore, during AF, BNP was known to be 
secreted mainly from the atrium in response to atrial wall stretch (Inoue et al., 2000). Our 
previous study in outpatients with paroxysmal AF showed that BNP levels during AF attack 
were increased 2.4 times compared with BNP levels during sinus rhythm (SR) (Tsuchida & 
Tanabe, 2004). Another study on electric defibrillation in patients with chronic AF showed 
an increase of about three times during AF than during SR after electric defibrillation (Ohta 
et al., 2001). These studies revealed that BNP levels during AF (both paroxysmal AF attack 
and chronic AF) are 2-3 times higher compared to during SR, and therefore BNP level 
during AF is the sum of the BNP level from the ventricle (reflecting left ventricular function) 
and the atrium (due to atrial wall stress).  
www.intechopen.com
 
Atrial Fibrillation - Basic Research and Clinical Applications 
 
208 
Some studies have shown that BNP levels have a prognostic value of mortality and 
morbidity in patients with chronic heart failure (Maeda et al., 2000; Anand et al., 2003), in 
general populations (Wang et al., 2004) and in clinical practice (Tsuchida & Tanabe, 2008).  
This study shows that BNP level in patients with AF is an important prognostic marker of 
cardiovascular events, cardiovascular mortality, all-cause mortality, heart failure, ischemic 
stroke and development of paroxysmal AF into chronic AF, by stratification into two groups 
based on routinely used cut-off levels of BNP (100pg/ml).  
The 14 year follow-up study of paroxysmal AF (Kato T et al., 2004) revealed that paroxysmal 
AF eventually developed into chronic AF in 132 of 171 patients (77.2%, 5.5% of patients per 
year), despite changing the drugs as necessary, and the development ratio was significantly 
increased by aging, an enlarged left atrium, myocardial infarction and valvular disease. In 
this study (5.4 year follow-up), paroxysmal AF developed into chronic AF in 39 of 231 
patients (16.9%, 3.1% of patients per year), and the development ratio was significantly 
higher in patients with a BNP≧100 pg/ml than a BNP<100 pg/ml. It is conceivable that the 
reason for lower development ratio in this study than in the former study, is because of less 
myocardial infarction (5% in this study versus 11% in the former study) and valvular 
disease (10% versus 20%).  
In patients with coronary heart disease, BNP levels were definitely associated with acute 
phase and outcome of myocardial infarction (Morita et al., 1993; Bibbins-Domingo et al, 
2003; Morrow et al., 2003; Suzuki et al., 2004). However, in this study, we did not find an 
association between BNP levels and the risk of coronary heart disease events in patients 
with AF, reflecting a similar finding in the report of the Framingham study in a community-
based population (Wang et al., 2004).  
4.2 Incidence of stroke in patients with paroxysmal AF and chronic AF 
Hohnloser et al. (2001) suggested that Warfarin therapy was needed in patients with 
paroxysmal AF, similarly as in those with sustained AF (Hohnloser et al., 2007). Meanwhile, 
another study showed that, if SR was maintained with antiarrhythmic therapy, the 
prognosis of the patients with paroxysmal AF for ischemic stroke was better than those with 
permanent AF (Komatsu et al., 2004). In this study, the incidence of ischemic stroke was 
significantly higher in patients with chronic AF than in those with paroxysmal AF. The 
reason for it was because of older age, the presence of more structural disease (valvular 
disease, DCM, prior pacemaker operation and CHF), more prior stroke and higher mean 
CHADS2 score in patients with chronic AF.  
This study showed that the incidence of ischemic stroke was significantly higher with a 
BNP≧100 pg/ml than with a BNP<100 pg/ml. In addition, in patients with paroxysmal AF, 
the incidence of ischemic stroke was significantly higher with a BNP≧100 pg/ml than with 
a BNP<100 pg/ml, whereas in patients with chronic AF, it was not significantly associated 
with the BNP levels.  
In our previous study (Tsuchida & Tanabe, 2004), BNP levels during AF attack in patients 
with paroxysmal AF are 2.4 times higher (due to atrial wall stretch) compared to during SR, 
and even an asymptomatic AF attack also showed substantial and significant BNP elevation 
(median BNP levels: 31 pg/ml during SR, 71 pg/ml during AF attack). These findings 
suggest that BNP elevation of unknown origin could be attributed to the occurrence of 
asymptomatic AF attack, and the incidence of AF attack may be higher in paroxysmal AF 
patients with a BNP≧100 pg/ml, besides the degree of left ventricular dysfunction. 
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Furthermore, in this study, the incidence of development of paroxysmal AF into chronic AF 
was significantly higher with a BNP≧100 pg/ml, and so paroxysmal AF with a BNP≧100 
pg/ml may be going to develop close to chronic AF.  
As to the mechanism of association between elevation of BNP levels and development of 
ischemic stroke in AF patients, there are a few reports. The recent studies demonstrated that 
BNP levels correlated negatively with left atrial appendage flow velocity in chronic AF 
patient, and suggested that pathological changes (such as hypertrophy, fibrosis and 
inflammation) in the atrial myocardium may also be underlying factors in elevated BNP 
secretion in patients with poor left atrial appendage function, and so BNP as a reflection of 
left atrial appendage function may be a useful marker to predict vulnerability to 
thromboembolism in AF patients (Frustaci et al., 1997; Shimizu et al., 2002). Further study 
needs to be performed as to the mechanism of association between elevation of BNP levels 
and development of ischemic stroke in AF patients. 
4.3 Warfarin therapy in patients with CHADS2 score of 0 or 1 
CHADS2 score is known to be very useful to decide the indication of warfarin therapy in 
patients with AF (Gage et al., 2001). The patients with CHADS2 score of 2 or more are 
recommended to take warfarin therapy, those with CHADS2 score of 1 to take warfarin or 
antiplatelet drugs, and those with CHADS2 score of 0 need not take any warfarin.  
Based on Kaplan-Meier analysis of five groups stratified by CHADS2 score (0, 1, 2, 3, 4-6), it 
was found that as CHADS2 score was higher, the cumulative event-free rate for ischemic 
stroke decreased significantly. Furthermore, in the patients with CHADS2 score of 0 or 1, the 
incidence of ischemic stroke was significantly higher with a BNP≥100 pg/ml than with a 
BNP < 100 pg/ml. So in the patients with CHADS2 score of 0 or 1, BNP may be useful as an 
aid in CHADS2 score to decide the indication of warfarin therapy for prevention to ischemic 
stroke.  
4.4 Study limitations 
The study population consisted of 371 outpatients of one local clinic in Japan. Although 
they were treated according to the accepted guidelines, it was unavoidable that this study 
showed a certain amount of bias in relation to patient background, diagnosis and 
treatment. 
5. Conclusion 
In patients with AF, BNP levels predicted the risk of cardiovascular events and death, 
except for coronary heart disease. Patients with chronic AF had a higher risk of ischemic 
stroke than patients with paroxysmal AF. BNP may be useful as an aid in CHADS2 score to 
decide the indication of warfarin therapy in patients with paroxysmal AF and in patients 
with CHADS2 score of 0 or 1. 
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